MedTrace Logo

Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia

NCT01605864 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2014-03-24

No results posted yet for this study

Summary

Community-acquired bacterial pneumonia, which is often called CAP, is a bacterial infection in the lungs and is treated with antibiotics. Sometimes people need to be in the hospital to be treated for CAP. Usually, hospitalized persons with CAP are given two antibiotics together. These antibiotics usually include a cephalosporin and a macrolide. The most commonly used cephalosporin at Albany Medical Center Hospital is ceftriaxone. The most commonly used macrolides at Albany Medical Center Hospital are azithromycin and doxycycline.

This research is being done to find out how well a new cephalosporin antibiotic, called ceftaroline, works in combination with a macrolide for the treatment of CAP. Ceftaroline is similar to ceftriaxone. Ceftaroline was recently approved by the FDA to treat pneumonia in hospitalized patients based on two research studies. In one study, ceftaroline was better than ceftriaxone. In the second study, ceftaroline was just as good as ceftriaxone. Ceftaroline was very well tolerated in both clinical studies and it was found to be as safe as ceftriaxone.

Conditions

  • Community Acquired Bacterial Pneumonia

Interventions

DRUG

Efficacy of ceftaroline

Determining the efficacy of ceftaroline compared to other cephalosporins

Sponsors & Collaborators

  • Albany College of Pharmacy and Health Sciences

    collaborator OTHER

  • Forest Laboratories

    collaborator INDUSTRY

  • Albany Medical College

    lead OTHER

Principal Investigators

  • Wayne Triner, DO, MPH · Albany Medical College

  • Tom Lodise, PharmD · Albany College of Pharmacy and Health Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01605864 on ClinicalTrials.gov